Pneumoconiosis

Pneumoconiosis Causes

Pneumoconiosis causes

Common Pneumoconiosis Causes

While many lung diseases have several causes, pneumoconiosis has one specific trigger: the inhalation of toxic dust particles. When dust accumulates in the lungs, it can trigger an inflammatory reaction and the production of excess scar tissue. Pneumoconiosis causes a gradual loss of lung function and a variety of uncomfortable symptoms.

There are many different types of dust particles that have been associated with pneumoconiosis. These include:

  • Silica
  • Asbestos
  • Graphite
  • Iron
  • Coal
  • Barium

Because exposure to these dust particles most frequently occurs at industrial worksites, pneumoconiosis is considered to be an occupational lung disease. Most people who develop the condition have experienced routine, high-dose exposures over the course of many years.

Early-stage pneumoconiosis usually only causes a few minor symptoms, such as an occasional cough. More advanced forms of the disease, however, involve significantly more scarring and inflammation, and, as a result, more frequent and noticeable symptoms. It’s common, for instance, to cough up phlegm or feel short of breath even while at rest.

Many traditional treatments that are available alleviate the symptoms that pneumoconiosis causes, but do not do much to slow the progression of the disease. However, while cellular therapy cannot reverse existing lung damage, it does have the potential to relieve inflammation, slow the progression of the disease, and improve a patient’s quality of life.

At the Lung Institute, we offer cellular therapy to help our patients Breathe EasierTM. Our caring team can help you determine if cellular therapy might be right for you. To learn more, contact the Lung Institute at 888-745-6697.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.